Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing ...

Proprietary products utilized in >275 clinical applications, including 45 new applications in 2017. Gilead/Kite, Iovance Biotherapeutics, bluebird bio, TiGenix, TissueGene, Adaptimmune, and many more ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen. BioLife is a publicly traded ...

Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to ...

BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has ...

BOTHELL, Wash., Sept. 24, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today ...

Repligen Corporation RGEN announced that it has entered into a definitive agreement to acquire Washington-based BioLife Solutions BLFS, a leading developer of bioproduction products and services, for ...

WALTHAM, Mass. and BOTHELL, Wash., July 22, 2026 (GLOBE NEWSWIRE)-- Repligen Corporation (NASDAQ: RGEN, "Repligen," or "the Company"), a life sciences company focused ...